23 results
Thumbnail

D1.76 - Contact dermatitis in diabetic patients with wearable devices: A single-centre study

Thumbnail

D1.87 - Kiwi allergy: A Comparative Analysis of Adult and Pediatric patients

Thumbnail

D1.77 - Hereditary Angioedema in Real Life: Unmet Needs from the Patient Perspective

Thumbnail

D1.78 - Non-Allergic Dermatologic Diagnoses Among Patients Presenting to an Allergy Immunology Outpatient Clinic: A Prospective Clinical Study

Thumbnail

D1.79 - Heterogeneity of Non-Allergic Non-Eosinophilic Asthma: Clinical Subphenotypes and Allergy Belief Patterns

Thumbnail

D1.82 - Pancake Syndrome: Molecular and Diagnostic Heterogeneity of Mite Sensitization

Thumbnail

D1.83 - Cannabis-related severe anaphylaxis without cutaneous manifestations: atypical sensitization profile and mast cell disorder differential diagnosis in a case report

Thumbnail

D1.84 - Invasion Meets Allergy: Cortaderia selloana as an Emerging Grass Aeroallergen

Thumbnail

D1.85 - Baseline lung function and clinical outcomes in Allergic Bronchopulmonary Mycosis: A real-world cohort from a Severe Asthma Multidisciplinary Unit

Thumbnail

D1.86 - Age-Related Features of Sensitization to Timothy Grass in Children According to Component-Resolved Diagnostics

Thumbnail

D1.88 - An unusual diagnostic aid for Hymenoptera venom genuine versus cross sensitization: the field sting

Thumbnail

D1.89 - Qualitative comparison between Euroline Respiratory Profile and Phadiatop for the screening of airborne allergies

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis

Thumbnail

D2.497 - Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial

Thumbnail

D2.498 - Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilizing Professional Care in Pediatric Patients Aged 2 to